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Abstract: Determining radiographic progression in primary malignant brain tumors has 
posed a significant challenge to the neuroncology community. Glioblastoma multiforme 
(GBM, WHO Grade IV) through its inherent heterogeneous enhancement, growth patterns, 
and irregular nature has been difficult to assess for progression. Our ability to detect tumor 
progression radiographically remains inadequate. Despite the advanced imaging 
techniques, detecting tumor progression continues to be a clinical challenge. Here we 
review the different criteria used to detect tumor progression, and highlight the inherent 
challenges with detection of progression. 
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1. Introduction 
Determining radiographic progression in primary malignant brain tumors has posed a significant 
challenge to the neuroncology community. Glioblastoma multiforme (GBM, WHO Grade IV), through 
its inherent heterogeneous enhancement, growth patterns, and irregular nature, has been difficult to 
assess for progression. With new immunotherapeutic therapies, stereotactic radiosurgery, anti-VEGF 
inhibitors, and chemotherapeutics providing efficacy in GBM, it has become more critical for the 
neuroncology community to quickly and accurately determine tumor progression [1,2]. Despite these 
advances in therapeutics, our ability to detect tumor progression radiographically remains inadequate. 
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Despite the advanced imaging techniques, detecting tumor progression continues to be a clinical 
challenge. Here we review the different criteria used to detect tumor progression, and highlight the 
inherent challenges with detection of progression.  
2. MRI Imaging of Enhancement 
After a GBM surgical resection, patients receive serial MRI scans to assess for changes in 
enhancement. An MRI scan should be performed within 48 hours of surgical resection to assess 
baseline enhancement and assess for postoperative infarcts. Unlike CT scans that have a straight linear 
correlation between iodine concentration and Hounsfield units of enhancement, MRI has an inherent 
difficultly in determining a cutoff to judge enhancement. Enhancement on MRI scan and tissue 
concentration of Gd-DTPA have a complex relationship, that is bimodal in nature with an initial 
increased enhancement in signal intensity with contrast and then a decrease after a point [3]. The 
enhancement seen on MRI is not restricted to the tumor itself but includes the vasculature, 
parenchyma, and nasal mucosa. Blood products in the tumor may also produce signal changes similar 
to enhancing tissue. These challenges make quantification of enhancement and changes in tumor 
appearance more difficult to appreciate by the neuroncology community. 
3. Pseudoprogression/Radionecrosis/Pseudoresponse 
When changes in enhancement are detected on MRI, there is difficulty in determining if there is 
true tumor recurrence, radiation necrosis, or pseudoprogression most often associated with 
Temozolomide treatment [4]. Pseudoprogression is a novel but well documented phenomena where 
new enhancement of tissue is detected usually within three months of radiation, but with necrosis or 
gliosis noted on biopsy. The incidence of pseudoprogression has been considerable with 32 out of  
103 patients or 31.1% of GBM patients recently reported [5]. Despite being a well documented 
phenomenon, the mechanism behind pseudoprogression continues to be poorly understood. The 
current theory is that chemotherapy and radiotherapy induce tumor and endothelial cell death creating 
secondary edema and increased vessel permeability localized to the tumor area [6].  
Conversely, radionecrosis can occur 3–12 months after radiotherapy [7]. Radionecrosis occurs 
where there is local tissue reaction after radiotherapy with signs of a disrupted blood-brain barrier and 
edema. Histopathology demonstrates gliosis, endothelial thickening, necrosis, edema and   
thrombosis [6]. 
Tumor progression, when assessed by measurement of tissue enhancement, will therefore not 
accurately quantify tumor burden if there is a significant amount of non-enhancing tumor. Even in 
enhancing tumors, there has recently been increasing use of anti-angiogenic agents such as 
bevacizumab that normalize vasculature and decrease enhancement leading to potential under- and 
over-interpretations [8]. Other authors have noted that since enhancement can change due to radiation 
necrosis, pseudoprogression, steroid treatment, or pseudoresponse, it is not always the case that 
enhancement reflects changes in the underlying tumor [9]. Difficulty visualizing non-enhancing tumor 
burden is a problem for most proposed methods of assessing tumor response, and some authors have 
proposed that response criteria in these situations may have to be altered to include both radiologic 
changes and measurements of circulating biomarkers [10].   Toxins 2011, 3                                      
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4. Current Methods of Assessing Tumor Progression 
4.1. Macdonald Criteria 
The MacDonald criteria for determining tumor progression is determined through assessing the 
increase in size of an enhancing tumor on consecutive MRI scans and clinical assessment. Treatment 
responses are divided into four categories: complete response, partial response, progressive disease, 
and stable disease. Complete response occurs when there is a disappearance of all enhancing tumor on 
consecutive MRI scans at least one month apart, off steroids, and the patient is neurologically stable or 
improved. Partial response occurs at a >50% reduction in size of enhancing tumor on consecutive MRI 
scans at least one month apart, steroids stable or reduced, and neurologically stable or improved. 
Progressive disease occurs when there is a >25% increase in size of enhancing tumor on consecutive 
MRI scans, patient is neurologically worse, and steroids stable or increased. Stable disease occurs in 
all remaining situations. The size of a tumor’s largest cross sectional area is used to assess for   
changes [4].  
There are inherent difficulties in the MacDonald criteria when used rigorously to determine tumor 
progression. The criteria cannot be applied to all clinical criteria especially when the contrast 
enhancing region does not encompass all biologically and clinically active disease. MRI enhancement 
is not specific towards glioma progression when inflammatory response, breakdown of the blood brain 
barrier, and other pathological responses demonstrate enhancing regions [11]. In addition, there is a 
great deal of interobserver variability when using the McDonald criteria to assess progression, with 
Vos et al. reporting a 65% and 55% correspondence of progression on CT and MRI, respectively [12].  
4.2. RECIST Criteria 
The RECIST Criteria, Response Evaluation Criteria in Solid Tumors, also classifies patients into 
four groups on repeat imaging. Complete response occurs with disappearance of all lesions with 
confirmation at four weeks. Partial response is a >30% decrease in the sum of the longest diameters of 
all lesions with confirmation at four weeks. Stable disease is a decrease of less than 30% or an increase 
of less than 20% in the sum of the longest diameters of all lesions. Progressive disease is an >20% 
increase in the sum of the longest diameter of all lesions (Figure 1) [13].  
The pitfalls with the RECIST criteria include the difficulty of measuring cystic GBM lesions that do 
not encompass the entire diameter of enhancement. In addition, GBM enhancement occurs as a rim 
enhancement phenomenon where a considerable variability would exist in determining the diameter  
of tumor. 
4.3. WHO Criteria 
The WHO developed a response criteria on MRI images that used the sum of the estimated areas of 
all lesions based on the longest diameter by the greatest perpendicular diameter. Patients were 
classified into four groups. Complete response is defined as disappearance of all lesions as determined 
by two MRIs at least four weeks apart. Partial response is ≥50% decrease in the sum of total tumor 
area by two MRIs at least four weeks apart. No change, which is equivalent to stable disease, is Toxins 2011, 3                                      
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defined as less than a 50% decrease or less than a 25% increase in the sum of total tumor area. 
Progressive disease is defined as ≥25% increase in the size of one or more lesions or the appearance of 
new lesions [14]. The WHO criteria has similar shortcomings as the RECIST criteria with the 
subjective nature of measuring tumor burden in the resection cavity, cystic tumor lesions, and is 
unclear about daughter lesions.  
Figure 1. Traditional Non-Volumetric Measurements do not Adequately Describe 
Residual Enhancement in Surgical Resection Cavities. (A) This schematic resection cavity 
has residual rim enhancement in gray. RECIST criteria measurement ‘A’ or ‘a’ or ‘b’ or 
Macdonald criteria measurement ‘A*B’ or ‘a*b’ would not adequately describe residual 
tumor volume and additional tumor growth around the rim or collapse of the resection 
cavity may be over- or under-interpreted. (B) Differences in axial slice acquisition also 
impact measurements made by traditional criteria more than volumetric measurements. 
One scan could obtain axial slice ‘c’ with enhancing tumor measurement ‘x’ but a 
subsequent scan in the same patient could obtain axial slice ‘d’, causing an incorrect 
assessment of tumor response. (Reprinted with permission from PLOSOne [15]). 
 
4.4. RANO Criteria 
The RANO response criteria were developed with the inherent pitfalls of conventional criteria 
assessing for only enhancing tumors. The inherent pitfalls of the conventional criteria particularly 
entail pseudoprogression from radiochemotherapy, lack of steroid factoring into response, and non-
enhancing tumor with anti-angiogenic therapies [16]. The RANO criteria develop MRI imaging 
characteristics to assess responses as follows. 
4.4.1. Complete Response 
Disappearance of all enhancing and non-measurable disease for a period of at least four weeks. 
Stable or improved nonenhancing lesions on T2/FLAIR lesions on same or lower dosage of steroids 
from baseline [16].   Toxins 2011, 3                                      
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4.4.2. Partial Response 
Greater than 50% decrease of enhancing tumor in diameter sustained for four weeks; no progression 
of non-measurable disease; no new lesions; and stable or improved T2/FLAIR lesions on same or 
lower dosage of steroids from baseline [16]. 
4.4.3. Stable Disease 
Stable T2/FLAIR lesions on same or lower dosage of steroids from baseline and clinically stable 
status [16].  
4.4.4. Progression 
The following criteria are met: greater than or equal to 25% increase in the sum of diameters of 
enhancing lesions on stable or increased steroid dosage, a significant increase in T2/FLAIR 
nonenhancing lesions, appearance of new lesions, or clear clinical deterioration [16].  
5. Challenges and Future of Tumor Progression Imaging 
Currently the standard of therapy for detecting tumor progression has been using the MacDonald 
RECIST, or WHO Criteria with contrast enhancing MRI studies. From this report, the accuracy of this 
methodology has significant interobserver variability, difficulty in interpretation, and poor specificity 
between radiation necrosis and tumor progression. However due to the availability of MRI scanners 
and the frequency of MRI scans in these patients, MRI progression has been predominantly used for 
clinical protocols to detect progression.  
The authors feel that MRI analysis needs to be improved to reduce the subjective calculation of 
diameters and enhancing volume on the scans. We recommend using volumetric software to assess 
changes in enhancing tumor volumes. This has inherent difficulties with variable enhancement levels 
and other areas of enhancement that include the nasal mucosa and blood products. Further 
investigation in volumetric changes needs to verified and utilized prospectively to detect   
tumor progression.  
Volumetric methods demonstrate promise in the response assessment of enhancing brain tumors. 
Such methods can account for enhancing tumor despite expected postoperative collapse of the 
resection cavity. Despite this detection of enhancing brain volumes, there is an inherent difficulty in 
assessing residual enhancement from blood in the resection cavity. These situations frequently occur in 
brain tumor patients after surgical resection and have been difficult to describe with traditional 
response assessment methods. 
Technical differences, such as contrast dose and gantry angle, for serial MRI scans can lead to the 
false appearance of changes in the amount of tumor enhancement. A cutoff for enhancement that is 
calculated from each scan can help minimize the variations in contrast bolus between different MRI 
scans. This increases the universability of a program that analyzes different MRI scans.  
Reproducibility continues to be a pitfall in calculating tumor volumes [12]. Vos et al. investigated 
this interobserver variability by assessing radiographic response criteria for 35 patients with gliomas 
using five experienced clinicians. The authors found a poor interobserver variability with an intraclass Toxins 2011, 3                                      
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correlation coefficient of 0.51 amongst clinicians assessing radiographic response using McDonald 
criteria [12]. This pitfall of interobserver variability increases the necessity for automation. In support 
of this, Schwartz et al. found that in CT assessment of solid tumors, techniques that employed 
increased automation obtained results that were more accurate and consistent than manual methods 
[17]. Other studies using automated CT volumetric methods in pulmonary tumors suggest superiority 
when compared to manual RECIST measurements [18,19]. For gliomas, Sorensen et al. found that a 
computer-assisted perimeter method of volume calculation produced less inter- and intra-user 
variability than a manual volumetric calculation that used diameter measurements [20]. Other   
semi-automated tumor assessment methods, including automatic segmentation methods that use fuzzy 
clustering and interactive watershed algorithms, do not take into account tumor enhancement 
specifically [21–23]. This is due to the difficulty of the enhancement criteria of tumor amongst the 
segmented scans compared to normal parenchyma. 
An important difficulty with measuring enhancing brain tumors on MRI is that there is no 
quantitative cutoff for tissue enhancement on MRI. There have been a few previous descriptions of a 
formulaic determination of an enhancement threshold based on the initial peak enhancing signal 
increase, but this has not been widely accepted [24,25]. Many previous methods have simply utilized 
expert opinion to select the enhancing tissue according to their best judgment, however this technique 
invites significant subjective error, as different experts may have different opinions. Use of a standard 
threshold has precedence in other fields. With positron emission tomography (PET) scans, the detected 
intensity tapers off over distance from the source, so it is difficult to delineate precisely where the 
intensity is no longer apparent. A number of different methods have been attempted to estimate the 
tumor region of interest, and a set 40% threshold of either the source-to-background (S/B) ratio or of 
the maximum standardized uptake value (SUV) are commonly advocated techniques [26,27].  
There are concerns that the measurement of tissue enhancement will not accurately quantify tumor 
burden if there is a significant amount of non-enhancing tumor. Even in enhancing tumors, there has 
recently been increasing use of anti-angiogenic agents such as bevacizumab that normalize vasculature 
and decrease enhancement leading to potential over-interpretations [8,28,29]. Other authors have noted 
that since enhancement can change due to radiation necrosis, pseudo-progression, steroid treatment, or 
pseudo-response, enhancement does not always reflect changes in the underlying tumor [9]. The 
RANO criteria were drafted to attempt to address these limitations [30]. Difficulty visualizing   
non-enhancing tumor burden is a problem for most proposed methods of assessing tumor response, 
and some authors have advocated that response criteria in these situations may have to be altered to 
include both radiologic changes and measurements of circulating biomarkers [10]. Unfortunately, 
these limitations are equally applicable to the Macdonald or RECIST criteria. The initial paper by 
Macdonald et al. even acknowledges that their criteria should not be applied to non-enhancing tumor [4]. 
Determination of the magnitude and time course of these different changes may lead to greater ability 
to distinguish between actual disease recurrence and other causes of enhancing volume change. 
Pseudoprogression and radiation necrosis result in enhancement after radiation therapy and 
Temozolomide in patients with GBM. There is not a standard manner to differentiate these pathologies 
from tumor progression. The authors believe that a biomarker would be helpful in determining the 
difference between pseudoprogression and tumor progression. However this is a major pitfall and thus 
far can only be determined through a stereotactic brain biopsy.  Toxins 2011, 3                                      
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In the future, we would suggest that progression should be determined through an automated 
method determining radiographic characteristics of a tumor such as enhancement. In addition it is 
important that this tool would provide a high interuser reliability, therefore creating a consistent 
manner to determine radiographic progression. The authors reported on the novel technology called 
Velocity that uses volumetric software to determine tumor enhancement volumes (Figure 2) [15]. If 
there is a standard automated software that determines tumor progression, as a field we can transform a 
subjective interpretation into an objective analysis.  
Figure 2. Automated Assessment of Enhancing Tumor Volume. (A) T1-weighted   
post-contrast axial images are automatically fused with the pre-contrast sequences. (B) The 
tumor region of interest (blue area) and nearby normal brain (purple area) are outlined 
roughly by hand. (C) The enhancing nasal mucosa region is automatically detected with a 
built-in anatomic atlas (red area) and serves as a threshold for enhancement. (D) Tissue 
that is present on the post-contrast images but not the pre-contrast that is above the 
enhancement threshold appears in yellow. This includes enhancing tissue such as 
vasculature, tumor, and superficial structures. Enhancing tumor volume is defined as the 
green area within the manually-defined blue tumor region of interest. (Reprinted with 
permission from PLOSOne [15]). 
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